PTC Therapeutics Inc.'s Duchenne's muscular dystrophy (DMD) program looks to be the first casualty of Genzyme's Corp.'s acquisition by Sanofi SA, with the Cambridge, Mass.-based biotech handing back ex-North American rights to ataluren. Read More
The FDA's draft of PDUFA V was generally in line with expectations, particularly following the preview Janet Woodcock delivered to Congress in July. (See BioWorld Today, July 11, 2011.) Read More
By looking at how single-nucleotide polymorphisms (SNP) relate to the level of key metabolites in the blood, a multinational team of scientists identified nearly 40 variants that are associated with various metabolic traits. Read More
Peregrine Pharmaceuticals Inc., of Tustin, Calif., raised $7 million through a registered direct offering of 6.25 million shares priced at $1.11 apiece. Read More
SuperGen Inc., of Dublin, Calif., is changing its name to Astex Pharmaceuticals Inc. and its ticker symbol from SUPG to ASTX, effective Sept. 12. The change follows SuperGen's $120 million acquisition of privately held Astex Therapeutics Ltd. Read More
Dr. Reddy's Laboratories Ltd., of Hyderabad, India, initiated a randomized, double-blind, placebo-controlled Phase II trial of DRL-17822 in Type II diabetes. The primary outcome is elevation in HDL cholesterol and reduction in LDL cholesterol. Read More
Scientists from Stanford University have found that metabolites circulating in the blood affect brain aging through their effects on neural stem cells. Read More
